Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
234.1 USD | +2.13% | +4.79% | +1.17% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.92 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.52 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.17% | 42.65B | B | ||
+17.96% | 44.96B | B- | ||
+48.77% | 41.85B | A | ||
-4.27% | 29.04B | C | ||
+11.42% | 26.08B | B- | ||
-21.39% | 19.03B | B | ||
+4.86% | 12.75B | B+ | ||
+27.29% | 12.06B | C+ | ||
-3.50% | 11.75B | C+ | ||
+20.18% | 11.72B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IQV Stock
- Ratings Iqvia Holdings Inc.